Modifying Antiretroviral Therapy in Virologically Suppressed HIV-Infected Patients
Summary
- Some patients receiving atazanavir and low-dose ritonavir who experience adverse events may be successfully switched to unboosted atazanavir
- Studies have reported similar benefits of switching from a ritonavir-boosted PI to unboosted atazanavir[Cohen 2005; Gatell 2007; Sension 2009]
- ASSURE trial extended these findings by identifying significant reductions in bone and renal biomarkers following a switch from emtricitabine/tenofovir plus atazanavir/ritonavir to abacavir/lamivudine plus unboosted atazanavir[Wohl 2014]
Action required
- Login now to access all of your entitled content
or - View additional options to gain access to this content